Instrument Inactif

Communiqués Signal Genetics Inc Nasdaq

Actions

US8266401046

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

30/06	Le Lumvoa de Viridian Therapeutics pourrait générer des revenus significatifs dès 2027, selon RBC	MT
30/06	VIRIDIAN THERAPEUTICS, INC. : RBC Capital Markets favorable sur le dossier	ZM

Communiqués

27/06	Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease	BU
27/05	Viridian Therapeutics to Participate in Upcoming June Investor Conferences	BU
07/05	Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million	BU
05/05	Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock	BU
05/05	Viridian Therapeutics : REVEAL-2 Phase 3 Topline Results (Presentation)	PU
05/05	Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease	BU
05/05	Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress	BU
30/03	Viridian Therapeutics : REVEAL-1 Phase 3 Topline Results (Presentation)	PU
30/03	Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease	BU
26/02	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results	BU
08/01	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
06/01	Viridian Therapeutics Prepares for Transformational 2026	BU
22/12	Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease	BU
05/12	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
07/11	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05/11	Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress	BU
03/11	Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease	BU
22/10/25	Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock	BU
21/10/25	Viridian Therapeutics Announces Proposed Underwritten Public Offering	BU
20/10/25	Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million	BU
02/10/25	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
15/09/25	Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates	BU
03/09/25	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
06/08/25	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results	BU
05/08/25	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ